Autopsy report · NCT00447187

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

“The primary efficacy endpoint was not met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 7 months before it stopped.
• 368 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Lux Biosciences, Inc.

Sponsor type

Industry

Conditions

Corneal Diseases; Cornea Transplant

Interventions

LX201; Placebo

Participants

368

Sites

30

Countries

Germany, United States

Trials that died the same way

• Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
  “Lack of efficacy - Futility endpoint reached” (82% match in meaning)
• Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
  “Study met predefined futility criteria for efficacy endpoints.” (71% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (68% match in meaning)
• PleuraSeal Pivotal Study (US)
  “Interim analysis results were not supportive of primary endpoint” (68% match in meaning)
• Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
  “The trial met its primary endpoint.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.